Coldstream Capital Management Inc. Trims Stake in Moderna, Inc. (NASDAQ:MRNA)

Coldstream Capital Management Inc. cut its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 17.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,609 shares of the company’s stock after selling 745 shares during the period. Coldstream Capital Management Inc.’s holdings in Moderna were worth $236,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of MRNA. Geode Capital Management LLC lifted its position in shares of Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares in the last quarter. Groupama Asset Managment lifted its holdings in Moderna by 29.1% during the third quarter. Groupama Asset Managment now owns 21,838 shares of the company’s stock valued at $1,459,000 after purchasing an additional 4,920 shares in the last quarter. Nomura Asset Management Co. Ltd. boosted its position in shares of Moderna by 1.5% in the third quarter. Nomura Asset Management Co. Ltd. now owns 114,335 shares of the company’s stock worth $7,641,000 after purchasing an additional 1,635 shares during the period. Y Intercept Hong Kong Ltd increased its stake in shares of Moderna by 30.9% in the third quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company’s stock worth $6,760,000 after purchasing an additional 23,881 shares in the last quarter. Finally, MML Investors Services LLC raised its position in shares of Moderna by 21.6% during the 3rd quarter. MML Investors Services LLC now owns 33,895 shares of the company’s stock valued at $2,265,000 after purchasing an additional 6,018 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Up 0.0 %

Shares of MRNA stock opened at $41.84 on Tuesday. The company has a market cap of $16.10 billion, a PE ratio of -7.19 and a beta of 1.58. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47. The stock’s 50 day simple moving average is $48.26 and its two-hundred day simple moving average is $83.22. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.39) EPS. Research analysts predict that Moderna, Inc. will post -9.3 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a report on Monday, November 18th. TD Cowen cut their target price on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Sanford C. Bernstein initiated coverage on Moderna in a report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target on the stock. Wolfe Research began coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Finally, Bank of America reissued an “underperform” rating and issued a $41.00 target price on shares of Moderna in a report on Tuesday, December 10th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus target price of $79.50.

Insider Activity

In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,379 shares of company stock valued at $158,195. 15.70% of the stock is currently owned by company insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.